DBMI chair Casey Greene, interim director of the Center for Personalized Medicine, said the center’s work, in addition to benefiting researchers and patients, has the potential to reduce health care spending by reducing hospitalizations and other medical care related to bad drug-gene interactions. “There’s not that many win-wins in the health care system where payers can pay less and patients can get better care,” Greene said. “This is actually a win-win.”
